We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ip Group Plc | LSE:IPO | London | Ordinary Share | GB00B128J450 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.60 | 3.39% | 48.85 | 48.60 | 48.70 | 49.55 | 47.55 | 47.55 | 5,521,185 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | -140.1M | -174.4M | -0.1682 | -2.89 | 503.94M |
TIDMIPO
IP Group PLC
26 May 2020
FOR RELEASE ON 26 May 2020
Portfolio company Inivata announces strategic collaboration and $25m investment from NeoGenomics
IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is pleased to note that portfolio company Inivata Ltd, ("Inivata" or "the Company"), a leader in liquid biopsy, has announced the formation of a strategic collaboration with NeoGenomics, Inc (NASDAQ: NEO) for the commercialisation of its InVisionFirst(R)-Lung liquid biopsy test in the United States.
As part of the collaboration, NeoGenomics will make a $25 million equity investment in Inivata to take a minority shareholding with an option to buy the company outright. The new funding received by Inivata will be used to enable the acceleration of its liquid biopsy products, including further development work on RaD aR, its newly launched highly sensitive personalised assay for the detection of residual disease and recurrence.
Following completion of the initial equity investment, IP Group will hold a direct undiluted beneficial stake of 25.7% in Inivata. The directors expect that this transaction will result in a direct unrealised fair value gain to the Group of approximately GBP7.0 million and that the Group's holding will be valued at approximately GBP31.0 million.
NeoGenomics and Inivata will also seek opportunities for collaboration with biopharmaceutical companies around Inivata's liquid biopsy platform drawing on both companies' technology and expertise.
For more information, please contact:
IP Group plc www.ipgroupplc.com +44 (0) 20 7444 0050 Alan Aubrey, Chief Executive Officer Greg Smith, Chief Financial Officer +44 (0) 20 7444 0062/+44 (0) Liz Vaughan-Adams, Communications 7979 853802 Charlotte Street Partners Andrew Wilson +44 (0) 7810 636995 David Gaffney +44 (0) 7854 609998
Notes for editors
About IP Group
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.
For more information, please visit our website at www.ipgroupplc.com .
ENDS
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NRAUVSRRRVUVUUR
(END) Dow Jones Newswires
May 26, 2020 05:05 ET (09:05 GMT)
1 Year Ip Chart |
1 Month Ip Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions